Optimising multi pronged drug intercepts in AMD

Age-related macular degeneration (AMD) is the most common cause of blindness in the elderly population worldwide. The clinical spectrum of AMD comprises of drusen, hyperplasia of the retinal pigment epithelium (RPE), atrophy and choroidal neovascularization (CNV). These changes affect the macula of the retina and subsequently may affect central or reading visual acuity. The pharmacological therapies include photodynamic therapy (PDT), steroids, vascular endothelial growth factor (VEGF) inhibitors, extracellular matrix(ECM) modifiers, gene therapy and nutrition supplements.

Keywords: Agerelated macular degeneration (AMD), ie2 (Tyrosineprotein kinase) anti VEGF ranibizumab bevacizumab aflibercept.